- Home
- CISO vs LPCN Comparison
CISO vs LPCN Comparison
Compare CISO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- LPCN
- Stock Information
- Founded
- CISO 2015
- LPCN 1997
- Country
- CISO United States
- LPCN United States
- Employees
- CISO N/A
- LPCN N/A
- Industry
- CISO Computer Software: Prepackaged Software
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- LPCN Health Care
- Exchange
- CISO Nasdaq
- LPCN Nasdaq
- Market Cap
- CISO 32.7M
- LPCN 27.1M
- IPO Year
- CISO N/A
- LPCN N/A
- Fundamental
- Price
- CISO $1.03
- LPCN $4.37
- Analyst Decision
- CISO
- LPCN Strong Buy
- Analyst Count
- CISO 0
- LPCN 1
- Target Price
- CISO N/A
- LPCN $10.00
- AVG Volume (30 Days)
- CISO 312.9K
- LPCN 34.0K
- Earning Date
- CISO 11-18-2024
- LPCN 03-06-2025
- Dividend Yield
- CISO N/A
- LPCN N/A
- EPS Growth
- CISO N/A
- LPCN N/A
- EPS
- CISO N/A
- LPCN N/A
- Revenue
- CISO $54,633,909.00
- LPCN $7,922,926.00
- Revenue This Year
- CISO $78.76
- LPCN N/A
- Revenue Next Year
- CISO N/A
- LPCN N/A
- P/E Ratio
- CISO N/A
- LPCN N/A
- Revenue Growth
- CISO 34.87
- LPCN N/A
- 52 Week Low
- CISO $0.26
- LPCN $3.20
- 52 Week High
- CISO $3.84
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- CISO 36.83
- LPCN 38.51
- Support Level
- CISO $0.93
- LPCN $4.48
- Resistance Level
- CISO $1.39
- LPCN $4.89
- Average True Range (ATR)
- CISO 0.51
- LPCN 0.35
- MACD
- CISO -0.19
- LPCN -0.06
- Stochastic Oscillator
- CISO 3.30
- LPCN 9.60
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.